spacer
home > pmps > summer 2017 > labelling matters
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Labelling Matters

Patients with chronic conditions typically only adhere to 50-60% of medications as prescribed, despite irrefutable evidence that their treatments will increase life quality and expectancy. Non-compliance has been linked to worse health outcomes, more frequent hospitalisations and increased costs. Indeed, a 2003 WHO report stated that more health benefits worldwide would result from improving adherence to existing therapies than from the development of new ones (1). Any intervention that stimulates better compliance to essential medications – even slightly – may therefore play a meaningful role in enhancing public health.

Factors influencing non-adherence are varied, but largely predictable and range from the preventable, such as patients forgetting or misunderstanding, to the non-preventable, such as life-threatening side effects. However, one significant, but often overlooked, enabler of patient attrition is the label.

The importance of labelling gets very little exposure. Nonetheless, product packaging can be a key determinant of patient retention and better health outcomes. The rationale is straightforward: if someone cannot understand the instructions for use, they will be much more inclined to give up. As the cost of drug development escalates and budgetary pressure on the global healthcare economy grows, perhaps it is time for the pharmaceutical industry to review the role of the label in alleviating the expense and implications of patient attrition.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Mark Cusworth is the Vice President of R&D at PRISYM ID. He has over 15 years of experience heading up a team providing off-theshelf and tailored solutions to clinical trial companies. During this time, Mark has seen many changes to the industry, including significant tightening of regulations, challenges of globalisation as well as the shift from subject-based to interactive response technology trials. 
spacer
Mark Cusworth
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

BBI Solutions broadens antibody portfolio and strengthens reagent technical support capabilities with acquisition of Maine Biotechnology Services

BBI, a leading manufacturer of raw materials and finished test platforms, already provides human antigens, antibodies, serum and plasma products and clinical chemistry enzymes, for the in-vitro diagnostics market. Now with the acquisition of MBS they have strengthened their antibody offering, providing a comprehensive portfolio and custom services to deliver a total reagent solution for any immunoassay development.
More info >>

White Papers

SuperCapSyringe®

Weibel CDS AG

Safer, easier and faster drug delivery – Weibel CDS AG, Switzerland develops and produces innovative, user friendly, application oriented injections systems and devices. The SuperCapSyringe® product family upgrades your vial practically to a prefilled syringe. Based on a modular design, the syringe is fully adaptable to your application needs. It is supplied in different sizes and, as a novelty, with staked needles including a passive safety device.
More info >>

 
Industry Events

Pharma Packaging and Labeling East Coast 2018

21-22 February 2018, Philadelphia, USA

The 10th Annual Pharma Packaging and Labeling East Coast event aims to create an environment where commercial packaging and labeling teams work together to successfully manage both creative and regulatory demands while safeguarding products and protecting patients.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement